FDA and SEC Formalize Data Sharing to Boost Oversight
FDA and SEC signed an MOU establishing a framework to share nonpublic information.
Why it matters: This new collaboration improves regulatory enforcement and transparency for healthcare and securities markets, helping legal teams better manage compliance and investigations.
- MOU signed August 31, 2026, to share nonpublic information related to FDA-regulated products and activities.
- MOU aims to detect false or misleading public statements affecting investors involving FDA review and approvals.
- Agreement lasts three years and can be extended by mutual consent.
- Formalizes prior informal coordination between FDA and SEC to protect market integrity and public health.
On August 31, 2026, the SEC and FDA signed a Memorandum of Understanding (MOU) establishing a structured framework to share nonpublic information relevant to both agencies’ missions.
The collaboration is designed to help ensure market integrity and protect public health by enabling the agencies to coordinate on issues that impact both the securities and healthcare industries. This includes detecting potential false or misleading disclosures by companies regarding FDA reviews, product approvals, or clinical trial results, which are critical to investor decisions.
SEC Chairman Paul S. Atkins emphasized that “FDA-related disclosures by public companies have a significant impact on our markets,” highlighting the importance of this partnership. Acting FDA Commissioner Kyle Diamantas stated, “We are proud to partner with the SEC to enhance transparency across the life sciences sector.”
The MOU sets protocols for exchanging information while safeguarding confidentiality. It remains effective for three years and may be extended or adjusted by mutual written agreement. This agreement formalizes a previously informal relationship, signaling heightened regulatory coordination focused on publicly traded life sciences companies.
Legal and compliance teams in healthcare and securities should anticipate enhanced scrutiny of FDA-related disclosures, supported by this new data-sharing arrangement between the two agencies.
By the numbers:
- August 31, 2026 — Date of MOU signing
- 3 years — Duration of the MOU
- 3+ years — Potential for extension or modification by mutual consent